Keros Therapeutics (NASDAQ:KROS) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a strong sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Several other equities research analysts have also recently weighed in on KROS. Wells Fargo & Company decreased their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 27th. Leerink Partners cut their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Keros Therapeutics presently has a consensus rating of “Hold” and an average price target of $20.50.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $11.32 on Friday. The stock’s 50 day moving average is $10.81 and its 200 day moving average is $11.40. The firm has a market cap of $224.48 million, a P/E ratio of -3.06 and a beta of 1.01. Keros Therapeutics has a one year low of $9.69 and a one year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Equities analysts anticipate that Keros Therapeutics will post -5.27 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares in the company, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 5,893 shares of company stock valued at $60,507. Corporate insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its holdings in shares of Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after acquiring an additional 988 shares in the last quarter. UBS Group AG lifted its holdings in Keros Therapeutics by 1.1% during the third quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after acquiring an additional 1,091 shares during the period. Strs Ohio boosted its position in Keros Therapeutics by 3.9% in the fourth quarter. Strs Ohio now owns 29,300 shares of the company’s stock worth $597,000 after purchasing an additional 1,100 shares during the last quarter. California State Teachers Retirement System boosted its position in Keros Therapeutics by 72.6% in the second quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock worth $29,000 after purchasing an additional 1,148 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares during the period. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.